BusinessSun Pharma's Innovative Portfolio Expansion to Boost Stock Gains
Sun Pharma's outlook is set to improve due to scaling up its US portfolio, expanding its innovative drug range, and a tariff waiver on specialty drugs. A key trigger is its licensing deal with LIB Therapeutics to commercialize lerodalcibep, a cholesterol-lowering PCSK9 drug, opening a $3.7 billion market outside the US and China. The stock trades at 27 times FY28 earnings estimates and may gain from these developments.
Business Standard·2h ago



